Literature DB >> 8536297

Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally.

V Gallai1, P Sarchielli, A Floridi, M Franceschini, M Codini, G Glioti, A Trequattrini, R Palumbo.   

Abstract

We measured, by RIA methods, ictal and interictal levels of substance P (SP), calcitonin-gene related peptide (CGRP) and neurokinin A (NKA) in the plasma of 30 young migraine patients with aura (MPA) and 45 migraine patients without aura (MWA), and compared the results with those of 30 age-matched controls. There were no significant differences between the levels of these vasoactive peptides in the control group and the levels in both migraine groups studied in headache-free periods. An elevation of CGRP levels in plasma was found during attacks in MPA and, to a lesser extent, in MWA (p < 0.03 and p < 0.05, respectively). A significant increase in NKA levels was also demonstrated in the MPA and MWA groups (p < 0.02 and p < 0.04, respectively). These data suggest, although indirectly, that CGRP and NKA could be involved in the pathogenesis of migraine attacks in juvenile migraine patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8536297     DOI: 10.1046/j.1468-2982.1995.1505384.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  51 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

Review 2.  Diencephalic and brainstem mechanisms in migraine.

Authors:  Simon Akerman; Philip R Holland; Peter J Goadsby
Journal:  Nat Rev Neurosci       Date:  2011-09-20       Impact factor: 34.870

Review 3.  Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches.

Authors:  Peter J Goadsby
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Headache-type adverse effects of NO donors: vasodilation and beyond.

Authors:  G Bagdy; P Riba; V Kecskeméti; D Chase; G Juhász
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

Review 5.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

6.  Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism.

Authors:  S Akerman; D J Williamson; P J Goadsby
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

Review 7.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

Review 8.  Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications.

Authors:  L Edvinsson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

9.  Randomized, controlled trial of telcagepant for the acute treatment of migraine.

Authors:  K M Connor; R E Shapiro; H-C Diener; S Lucas; J Kost; X Fan; K Fei; C Assaid; C Lines; Tony W Ho
Journal:  Neurology       Date:  2009-09-22       Impact factor: 9.910

10.  Genetic enhancement of calcitonin gene-related Peptide-induced central sensitization to mechanical stimuli in mice.

Authors:  Blanca Marquez de Prado; Donna L Hammond; Andrew F Russo
Journal:  J Pain       Date:  2009-07-22       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.